Research-use-only context. This article summarizes published third-party scientific literature and laboratory practice. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. US Prime Peptides products are supplied strictly for in vitro laboratory research and are not for human or veterinary use.
A sterility line on a peptide certificate usually reads "Sterility: Pass (USP <71>)". This article explains what the compendial test actually does, how a laboratory chooses between membrane filtration and direct inoculation, why the incubation runs 14 days, how many units of a lot are sampled, and why the statistics of that sample make sterility a statement about a lot rather than a guarantee about any single vial.
What the USP <71> sterility test measures
The USP <71> sterility test asks one question: do viable, culturable microorganisms grow when a sample of the product is placed in two general-purpose growth media and incubated for at least 14 days? It does not count organisms, identify them, or detect non-viable residue such as endotoxin. A pass means no turbidity or other visible growth appeared in any test container during the incubation period.
The chapter is harmonized with European Pharmacopoeia 2.6.1 and Japanese Pharmacopoeia 4.06, and the ICH Q4B Annex 8 evaluation regards the three texts as interchangeable within the ICH regions. The United States Pharmacopeia publishes the chapter as General Chapter <71> Sterility Tests; portions that remain unharmonized are flagged with symbols in the official text. For biological products regulated under 21 CFR 610.12, the regulation requires that the method be validated, that written procedures define sample number, volume and container size, and that a positive first result is a failure unless an investigation definitively attributes it to laboratory error, after which one repeat is permitted.
Two features distinguish sterility from the other microbiological line on a certificate. Sterility is a culture test for living organisms; the endotoxin test described in endotoxin testing (LAL and recombinant Factor C) detects heat-stable lipopolysaccharide left behind by Gram-negative bacteria whether or not the bacteria survived. A lot can pass one and fail the other.
Two media, two temperatures, fourteen days
Every USP <71> test uses the same pair of media. Fluid Thioglycollate Medium (FTM) is incubated at 30 to 35 °C and supports anaerobic and many aerobic bacteria; its reducing environment and low-oxygen zone at the bottom of the tube allow organisms such as Clostridium to grow. Soybean-Casein Digest Medium (SCDM, also called tryptic soy broth) is incubated at 20 to 25 °C and favors aerobic bacteria, yeasts and molds. The incubation period is not less than 14 days for both.
| Medium | Incubation | Primary targets | Growth-promotion strains (examples) |
|---|---|---|---|
| Fluid Thioglycollate Medium | 30 to 35 °C, 14 days minimum | Anaerobic and aerobic bacteria | Staphylococcus aureus, Pseudomonas aeruginosa, Clostridium sporogenes |
| Soybean-Casein Digest Medium | 20 to 25 °C, 14 days minimum | Aerobic bacteria, yeasts, molds | Bacillus subtilis, Candida albicans, Aspergillus brasiliensis |
The 14-day period exists because stressed or slow-growing organisms, especially molds and spore-formers that have survived processing, can take well over a week to produce visible turbidity. England and colleagues reported in the Journal of Clinical Microbiology in 2019 that, against a panel of 118 challenge organisms representative of a manufacturing environment, the compendial USP <71> method detected 84.7% within 96 hours (bacteria) or 144 hours (fungi), rising to 95.7% when incubation was extended to 360 hours with a terminal visual inspection. The remaining gap to 100% came mostly from molds, which is exactly the class the long incubation is designed to catch.
Each lot of medium must also pass a growth-promotion test with reference strains, and each product must pass a method-suitability (bacteriostasis and fungistasis) test showing that the product itself does not suppress growth of low inocula. Without that step, a preservative, a low pH, or a high salt load could mask contamination and produce a false pass.
Membrane filtration versus direct inoculation
Membrane filtration is the preferred method whenever the product can be passed through a filter; direct inoculation is used when it cannot. In membrane filtration, the reconstituted sample is drawn through a membrane with a nominal pore size of 0.45 µm or finer, the membrane is rinsed with a sterile diluent to remove any residual product that might inhibit growth, and the membrane (or halves of it) is transferred into each medium. In direct inoculation, a measured portion of the product is added straight into a volume of medium large enough that the product is diluted below any inhibitory concentration.
| Feature | Membrane filtration | Direct inoculation |
|---|---|---|
| Sample handling | Entire sample volume filtered; organisms concentrated on the membrane | Sample added directly to medium |
| Inhibitory products | Rinsing removes antimicrobial or preservative residue | Relies on dilution; may need neutralizers |
| Typical use for lyophilized peptides | Vial contents dissolved in sterile diluent, then filtered | Used when the dissolved product clogs or binds the membrane |
| Main failure mode | Product adsorbed on membrane inhibits growth if rinsing is inadequate | Insufficient dilution of an inhibitory product |
For a lyophilized peptide the laboratory dissolves the powder in a sterile, validated diluent before testing. The method-suitability study establishes which rinse volumes and diluent restore growth of the reference strains in the presence of the specific peptide. That study is product-specific, which is one reason a sterility report should name the method used, not just the chapter number.
How many vials are tested, and what the sample size can and cannot detect
USP <71> fixes the minimum number of units tested by batch size, and for a parenteral-type product in small containers the number tops out at 20 units for batches above 500 containers. Because the test is destructive, every unit tested is a unit that cannot be sold, and the sample is deliberately small. The consequence is statistical: a test of 20 units reliably detects only heavy contamination. FDA's 2004 guidance on sterile drug products produced by aseptic processing puts it plainly, quoting USP: the sampling plan "only enables the detection of contamination in a lot in which 10% of the units are contaminated about nine times out of ten in making the test", and adds that, because of the limited sensitivity of the test, any positive result is a serious issue to be thoroughly investigated.
| True fraction of contaminated units in the lot | Probability a 20-unit test shows no growth | Probability the test catches the problem |
|---|---|---|
| 10% | 0.920 ≈ 0.12 | ≈ 88% |
| 1% | 0.9920 ≈ 0.82 | ≈ 18% |
| 0.1% | 0.99920 ≈ 0.98 | ≈ 2% |
These figures are simple binomial arithmetic assuming contamination is spread randomly across units. They are the reason regulators regard the end-product sterility test as a confirmation of a controlled process rather than as the source of sterility assurance. Tidswell, Agalloco and Tirumalai argued in the PDA Journal of Pharmaceutical Science and Technology in 2022 that assurance comes from process design and monitoring, and that revisions to USP informational chapters <1211> and <1222> are moving the field toward parametric release for well-controlled processes. For a buyer reading a certificate, the practical reading is the same: a pass tells you the lot was sampled and no growth was found under the stated method, not that every vial in the lot has been individually proven sterile.
Rapid and alternative methods
Alternative sterility methods shorten time to result but must be validated against the compendial test before they can replace it. Automated blood-culture instruments that detect CO2 production, ATP bioluminescence, solid-phase cytometry and nucleic-acid amplification have all been evaluated. Bugno and colleagues reported in the Journal of Pharmaceutical Innovation in 2018 that an automated culture system detected the same challenge organisms as the pharmacopoeial test with no significant difference in detection ability, only faster. Deutschmann and colleagues described in 2023 a nine-step evaluation, qualification and validation route that two companies used to implement alternative sterility tests with roughly 50% shorter incubation, noting that both the European Medicines Agency and FDA had by then approved rapid sterility tests for lot release.
The England 2019 study is a useful caution: one automated system, optimized for clinical bloodstream isolates, detected only 71.2% of the environmental challenge panel even at 360 hours, and failed on molds that the compendial method caught. Gebo and Lau's 2020 minireview makes the same point from the clinical-laboratory side: a method validated for one product class and organism set is not automatically suitable for another. When a research-peptide certificate reports sterility by a rapid method, the report should state the method and the validation basis, and the buyer should read "USP <71>" on a report as meaning the compendial culture test unless the report says otherwise.
Reading the sterility line on a research-peptide certificate
A complete sterility entry names the chapter, the method (membrane filtration or direct inoculation), both media, the incubation period, the number of units tested and the result. "Sterility: Pass" with no method is an incomplete entry, and a certificate that reports sterility for a lot but endotoxin for a different lot is a mismatch worth querying, as discussed in what a lot number is for.
Three limits follow from the chemistry and statistics above. First, sterility is a lot-level, time-stamped statement: it describes sealed units sampled from the lot at the time of testing and says nothing about a vial after its stopper has been pierced in a laboratory. Second, the culture test is blind to non-culturable organisms, mycoplasma, viruses and endotoxin, each of which needs its own assay; see what a certificate of analysis does not test for. Third, a pass is strong evidence that the fill and finish process was under control, because the process and its environmental monitoring, not the end test, are what make most of the units sterile. US Prime Peptides reports sterility together with endotoxin, identity, purity, content and metals on a lot-matched certificate from an independent US laboratory, which is the combination a research buyer should expect; how to read a peptide certificate of analysis walks through the other lines.
Frequently Asked Questions
What does USP 71 sterility testing actually test for?
USP <71> tests whether viable, culturable bacteria, yeasts or molds grow from a product sample incubated in Fluid Thioglycollate Medium at 30 to 35 °C and Soybean-Casein Digest Medium at 20 to 25 °C for at least 14 days. It does not detect endotoxin, viruses or non-culturable organisms, and it does not identify or count the organisms it finds.
Why does a sterility test take 14 days?
Stressed, slow-growing and spore-forming organisms, especially molds, can take more than a week to produce visible growth. In a 2019 challenge study, the compendial method detected 84.7% of 118 organisms within four to six days and 95.7% only after the full incubation, so shortening the period would miss exactly the organisms the test is meant to catch.
Can a lot pass sterility testing and still contain a contaminated vial?
Yes. The test samples at most 20 units from a large lot, so it reliably detects only heavy contamination; FDA's aseptic-processing guidance notes the plan catches a lot with 10% contaminated units about nine times out of ten. Sterility assurance comes from a controlled process, with the end test as confirmation.
What is the difference between membrane filtration and direct inoculation?
Membrane filtration passes the dissolved sample through a 0.45 µm membrane, rinses the membrane to remove inhibitory product, and incubates the membrane in media; it is preferred whenever the product can be filtered. Direct inoculation adds the sample straight into a large volume of medium and is used when filtration is not practical.
Citations
- United States Pharmacopeia. General Chapter <71> Sterility Tests. USP-NF. Rockville, MD. doi.usp.org/USPNF/USPNF_M98810_01_01.html
- FDA. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice. 2004. fda.gov
- 21 CFR § 610.12 Sterility. Code of Federal Regulations. law.cornell.edu/cfr/text/21/610.12
- FDA, HHS. Amendments to sterility test requirements for biological products. Final rule. Fed Regist. 2012;77:26162-26175. PMID 22606719
- England MR, Stock F, Gebo JET, Frank KM, Lau AF. Comprehensive Evaluation of Compendial USP<71>, BacT/Alert Dual-T, and Bactec FX for Detection of Product Sterility Testing Contaminants. J Clin Microbiol. 2019;57(2):e01548-18. PMID 30541938
- Gebo JET, Lau AF. Sterility Testing for Cellular Therapies: What Is the Role of the Clinical Microbiology Laboratory? J Clin Microbiol. 2020;58(7):e01492-19. PMID 32321785
- Bugno A, Saes DPS, Almodovar AAB, et al. Performance Survey and Comparison Between Rapid Sterility Testing Method and Pharmacopoeia Sterility Test. J Pharm Innov. 2018;13:27-35. PMID 29497461
- Deutschmann S, Paul M, Claassen-Willemse M, et al. Rapid Sterility Test Systems in the Pharmaceutical Industry: Applying a Structured Approach to Their Evaluation, Validation and Global Implementation. PDA J Pharm Sci Technol. 2023;77:211-235. PMID 36697213
- Tidswell EC, Agalloco JP, Tirumalai R. Sterility Assurance-Current and Future State. PDA J Pharm Sci Technol. 2022;76:263-277. PMID 34531294
- Gray JC, Staerk A, Berchtold M, Hecker W, Neuhaus G, Wirth A. Growth-promoting Properties of Different Solid Nutrient Media Evaluated with Stressed and Unstressed Micro-organisms: Prestudy for the Validation of a Rapid Sterility Test. PDA J Pharm Sci Technol. 2010;64:249-263. PMID 21502025
This article is for laboratory research reference only. US Prime Peptides products are supplied strictly for in vitro research. Not for human consumption.
Related research
- What a Peptide Certificate of Analysis Does Not Test For
- TFA Salt vs Acetate Salt: Why the Counter-Ion on a Peptide Matters
- LC-MS Identity Confirmation: What the Mass Spectrum Proves About a Peptide
- How to Vet a Research Peptide Vendor: A 12-Point Checklist
- What a Lot Number Is For, and How to Match a Vial to Its Certificate
Compliance Notice: US Prime Peptides products are supplied strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.
